SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs stronger-than-expected quarterly results and rapid growth in its AI-compute business, alongside plans for an aggressive expansion, fueled a bullish reaction and a sharp after-hours move. Traders are divided over whether the growth outlook justifies the valuation given heavy capital spending, while some also point to a potential Tesla merger as an additional, uncertain catalyst.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly update sharply raised its sales outlook and gross-margin expectations on stronger AI-platform demand, driving a rally and renewed optimism about AI-server growth. Traders largely welcomed the update and debated potential short covering and the stocks valuation, while some remained cautious about whether the gains will hold and whether execution can be sustained.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix shares came under pressure after its earnings report paired a profit beat with a weaker fourth-quarter outlook and a lower advertising-revenue forecast. Traders focused on slowing growth and streaming competition, while some dip buyers argued the selloff was excessive given the companys continued profitability.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCN is drawing attention on a sharp price rebound and a renewed breakout attempt, with traders linking the move to Robinhood Chain and other payroll/payment partnerships. Bullish posts point to expanding adoption, while skeptics say sustained usage, trading volume and token demand still need to confirm the thesis; the Robinhood-related catalyst is also discussed with some uncertainty.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs Neutron first flight has been pushed to 2027 after a manufacturing defect in its carbon-composite propellant dome, with replacement work underway. Traders remain divided: some question execution and the lack of a firmer schedule, while others view the selloff as an overreaction and are buying for the long term.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grummans quarterly results beat expectations, its 2026 outlook was raised, and its backlog reached a record, driving the sharp move higher. Traders are weighing the strong results against a pullback from the session high and whether buyers can sustain the gains.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention is centered on TG Therapeutics MSToronto presentations, especially initial Phase 1 azer-cel data in progressive MS, alongside long-term BRIUMVI and other clinical updates. Traders are positioning ahead of the readouts, with some optimistic about azer-cels potential and others stressing that its clinical impact remains uncertain; ongoing BRIUMVI growth provides a commercial backdrop.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale is under pressure after Barclays downgraded the stock, citing commercial execution risks and delays in securing a definitive TVAENTRA1 agreement for the proposed deployment. Traders debate whether the selloff overstates the risk: bears point to the lack of firm project commitments, while bulls cite AI-driven power demand and NuScales longer-term nuclear opportunity.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is drawing attention ahead of its quarterly report, with traders focused on managements outlook and whether demand is improving after earlier weakness. Some see recent gains and bullish options activity as encouraging, while others worry the stock could fall again if results or guidance disappoint.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

FAA certification of Boeings 737 MAX 10 is the dominant catalyst, with bulls viewing it as a step toward deliveries and cash generation while skeptics say approval alone may not move the stock. Traders largely focus on whether Boeing can ramp production and convert its backlog into actual deliveries.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2026 on Thursday, October 29, 2026, before the U.S. financial markets open. Management will provide an update on the...

If You Invested $1000 In Alnylam Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 15 years by 12.41% on an annualized basis producing an average annual return of 25.61%. Currently, Alnylam Pharmaceuticals has a marketread more...

Interesting ALNY Put And Call Options For September 2027

Investors in Alnylam Pharmaceuticals Inc (Symbol: ALNY) saw new options become available today, for the September 2027 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 339 days until expiration the newly av...

argenx Meets Primary Endpoint in Phase II Celiac Disease Study

ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia 

Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.

ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study 

argenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.

Here's Why You Should Add LPCN Stock to Your Portfolio Now

Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.

ETON Stock Surges 108% in Six Months: Here's What You Need to Know

Eton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The failed trial studied Wainua in transthyretin amyloid cardiomyopathy or ATTR-CM.&nbsp;</li><li>Jefferies said in a note that the data presents a neutral to negative read-through to Alnylam, which is developing drugs for ATTR amyloidosis.</li><li>Jefferies said the results were mostly as expected and put more pressure on Alnylam’s TTR business.</li></ul>Shares of Alnylam Pharmaceuticals (ALNY) closed flat on Friday after full results from a failed cardiomyopathy trial conducted by Ionis Pharmaceuticals and AstraZeneca were presented in Munich.Jefferies said in a note that the data presents a neutral to negative readthrough to Alnylam, which is developing drugs for ATTR amyloidosis, targeting the same protein as Ionis and AstraZeneca’s eplontersen. &nbsp;Alnylam shares fell as much as 5% but closed Friday marginally higher. Ionis closed down 2%, and AstraZeneca’s U.S. shares slipped about 1%.<h2 class="st-heading-2">What Happened?</h2>Ionis and AstraZeneca already disclosed on July 9 that the late-stage CARDIO-TTRansform missed its primary goal. Friday’s ESC Congress Hot Line session and a simultaneous New England Journal of Medicine paper supplied the first complete data.The 1,432-patient study is the largest trial to date in transthyretin amyloid cardiomyopathy or ATTR-CM, a progressive and often fatal disease in which a misfolded protein builds up in the heart. Patients received a monthly injection of eplontersen (Wainua) or placebo for 140 weeks, on top of usual care. Wainua is co-developed and commercialized by Ionis and AstraZeneca.The main measure in the trial combined cardiovascular deaths and repeat cardiovascular events. There were 381 events in 210 patients on eplontersen versus 392 events in 231 patients on placebo. The difference was not statistically significant.The drug lowered circulating transthyretin as intended. Patients already on a stabilizer received no additional benefit. Those not on a stabilizer at the start had fewer events with eplontersen alone, a result that was only nominally significant. Safety was in line with earlier studies.Wainua remains approved for nerve damage caused by a rare, inherited disease where abnormal amyloid proteins build up in the body, called hereditary transthyretin-mediated amyloidosis.<h2 class="st-heading-2">Wall Street Weighs In On Impact For ALNY</h2>Jefferies said the results were mostly as expected and put more pressure on Alnylam’s TTR business — its drugs for ATTR amyloidosis, a disease in which a misfolded liver protein builds up in the heart or nerves. Alnylam’s main drug, Amvuttra, is a silencer that tells the liver to make less of that protein. The data raise doubts that silencers should be the usual next step after stabilizer pills already used as standard care, and they add risk to TRITON-CM, Alnylam’s late-stage trial of its next silencer in heart patients.The firm kept a Hold rating and a $230 price target on ALNY.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ALNY remained in ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.Sentiment around IONS and AZN remained ‘neutral’ at the time of writing.While <a href="https://stocktwits.com/symbol/ALNY">ALNY stock</a> has fallen 41% year-to-date, <a href="https://stocktwits.com/symbol/AZN">AZN</a> has fallen 7% and <a href="https://stocktwits.com/symbol/IONS">IONS</a> 23%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/crsp-stock-slips-3-despite-encouraging-ctx-310-data-morgan-stanley-says-investor-focus-is-further-ahead/cZYASrNRJAU">CRSP Stock Slips 3% Despite ‘Encouraging’ CTX310 Data — Morgan Stanley Says Investor Focus Is Further Ahead</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Alnylam Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Ionis and AstraZeneca already disclosed on July 9 that the late-stage CARDIO-TTRansform missed its primary goal. Full data from the trial was unveiled on Friday.

AstraZeneca PLC

Ionis Pharmaceuticals Inc

Track ALNY stock price, charts, news and real-time market activity on Stocktwits. Join the ALNY message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Alnylam Pharmaceuticals Inc stock.

ALNY Stock Price Today - Alnylam Pharmaceuticals Inc News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$230.71
Prev Close	$233.29
Open	$237.73
Dividend Yield	0.00%
50-Day Moving Average	$238.97
Beta	0.75
Avg. Volume	1.48M
PE Ratio	38.95

52-Week High	$485.36
52-Week Low	$197.81
Market Capitalization	$31.22B
EPS (Annual)	$2.33
Price to Book	22.79
Revenue Per Employee	$1.49M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALNY Fundamentals